Trial Review

Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements. New passwords must include at least one lowercase letter, one uppercase letter, one number and one special character (e.g. !#$%&@).
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05551117




Registration number
NCT05551117
Ethics application status
Date submitted
19/09/2022
Date registered
22/09/2022
Date last updated
25/03/2025

Titles & IDs
Public title
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
Scientific title
A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Secondary ID [1] 0 0
CP-MGC018-03
Universal Trial Number (UTN)
Trial acronym
Tamarack
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Castration-Resistant Prostatic Cancer 0 0
Androgen-Independent Prostatic Cancer 0 0
Androgen-Insensitive Prostatic Cancer 0 0
Androgen-Resistant Prostatic Cancer 0 0
Hormone Refractory Prostatic Cancer 0 0
Anal Cancer 0 0
Anal Neoplasm 0 0
Carcinoma, Squamous Cell of Head and Neck 0 0
Head and Neck Squamous Cell Carcinoma 0 0
Laryngeal Squamous Cell Carcinoma 0 0
Oral Squamous Cell Carcinoma 0 0
Malignant Melanoma 0 0
Melanoma 0 0
Non-small Cell Lung Cancer 0 0
Non-small Cell Carcinoma 0 0
Small-cell Lung Cancer 0 0
Small Cell Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell
Cancer 0 0 0 0
Prostate
Cancer 0 0 0 0
Malignant melanoma
Cancer 0 0 0 0
Head and neck
Cancer 0 0 0 0
Bowel - Anal

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - vobramitamab duocarmazine 2.0 mg (Arm A)
Treatment: Other - vobramitamab duocarmazine 2.7 mg (Arm B)
Treatment: Other - vobramitamab duocarmazine
Treatment: Drugs - Abiraterone
Treatment: Drugs - Enzalutamide

Experimental: Part 1: MGC018 2.0 mg (Arm A) - MGC018 2.0 mg/kg every 4 weeks

Experimental: Part 1: MGC018 2.7 mg (Arm B) - MGC018 2.7 mg/kg every 4 weeks

Experimental: Part 2 - MGC018 2.7 mg/kg every 4 weeks

Active comparator: Part 1: Control Arm - Patients are administered abiraterone or enzalutamide


Treatment: Other: vobramitamab duocarmazine 2.0 mg (Arm A)
2.0 mg/kg intravenous (IV) every 4 weeks

Treatment: Other: vobramitamab duocarmazine 2.7 mg (Arm B)
2.7 mg.kg IV every 4 weeks

Treatment: Other: vobramitamab duocarmazine
2.7 mg.kg IV every 4 weeks

Treatment: Drugs: Abiraterone
1000 mg once daily

Treatment: Drugs: Enzalutamide
160 mg daily
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part 1: Radiographic progression free survival (rPFS) as determined by the investigator
Assessment method [1] 0 0
The landmark analysis for 6 month rPFS rate will occur when all participants on Part 1 have been on study for at least 6 months. rPFS is defined as the time from the date of randomization to the date of first documented progressive disease (PD) per Prostate Cancer Working Group 3 (PCWG3) or death from any cause, whichever occurs first.
Timepoint [1] 0 0
Every 8 weeks for the first 24 weeks, then every 12 weeks, up to 2 years
Primary outcome [2] 0 0
Part 2: Objective response rate (ORR) per investigator assessment of Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria
Assessment method [2] 0 0
The ORR is defined as the percentage of participants in the response evaluable population who achieve a best overall response of conplete response (CR) or partial response (PR), per RECIST version 1.1 criterial CR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease from baseline in the sum of diameters of target lesions.
Timepoint [2] 0 0
Every 8 weeks for the first 24 weeks, then every 12 weeks, up to 2 years
Secondary outcome [1] 0 0
Part 1: ORR per PCWG3 criteria as determined by the investigator
Assessment method [1] 0 0
The percentage of participants experiencing a complete response (CR) or partial response (PR) to treatment. CR + PR = ORR
Timepoint [1] 0 0
Every 8 weeks for the first 24 weeks, then every 12 weeks, up to 2 years
Secondary outcome [2] 0 0
Part 1: Median duration of response (DoR) per PCWG3 criteria as determined by the investigator
Assessment method [2] 0 0
The DoR will be calculated as the time from the date of initial tumor response (CR or PR) to the date of first documented PD or death from any cause, whichever occurs first.
Timepoint [2] 0 0
Every 8 weeks for the first 24 weeks, then every 12 weeks, up to 2 years
Secondary outcome [3] 0 0
Part 1: Tumor size change over time
Assessment method [3] 0 0
Timepoint [3] 0 0
Every 8 weeks for the first 24 weeks, then every 12 weeks, up to 2 years
Secondary outcome [4] 0 0
Part 1: Prostate-specific Cancer Antigen (PSA) response rate per PCWG3 criteria
Assessment method [4] 0 0
PSA response is defined as a = 50% decline in PSA from baseline with PSA confirmation = 3 weeks after the first documented reduction in PSA of = 50%.
Timepoint [4] 0 0
Every 4 weeks throughout study participation, up to 2 years
Secondary outcome [5] 0 0
Part 1: Time to PSA progression per PCWG3 criteria
Assessment method [5] 0 0
In participants with a decrease in PSA from baseline, PSA progression is defined as a = 25% increase and an absolute increase of = 2 ng/mL above the nadir value, which is confirmed by a consecutive second value obtained = 3 weeks later. In participants with no decrease in PSA from baseline, PSA progression is defined as a = 25% increase and an absolute increase of = 2 ng/mL above the baseline value after 12 weeks. Time to PSA progression is defined as the time from the date of randomization to the first PSA progression.
Timepoint [5] 0 0
Every 4 weeks throughout study participation, up to 2 years
Secondary outcome [6] 0 0
Part 1: Duration of PSA response per PCWG3 criteria
Assessment method [6] 0 0
Duration of PSA response is defined as the time from the date of first documented PSA response to the earliest date of PSA progression.
Timepoint [6] 0 0
Every 4 weeks throughout study participation, up to 2 years
Secondary outcome [7] 0 0
Part 1: PSA percent change over time
Assessment method [7] 0 0
Timepoint [7] 0 0
Every 4 weeks throughout study participation, up to 2 years
Secondary outcome [8] 0 0
Part 1: Time to first symptomatic skeletal event (SSE)
Assessment method [8] 0 0
An SSE is defined as any of the following events: new symptomatic pathological fracture, requirement for radiation therapy to relieve bone pain, spinal cord compression, or tumor-related orthopedic surgical intervention. The time to first SSE is defined as the time from the date of randomization to the first occurrence of SSE.
Timepoint [8] 0 0
Every 4 weeks throughout the study, up to 2 years
Secondary outcome [9] 0 0
Number of participants with adverse event (AEs), serious AEs (SAEs), and AEs leading to study treatment discontinuation.
Assessment method [9] 0 0
Timepoint [9] 0 0
Throughout the study, up to 2 years
Secondary outcome [10] 0 0
Number of participants who develop anti-drug antibodies
Assessment method [10] 0 0
Timepoint [10] 0 0
Throughout the study, up to 2 years
Secondary outcome [11] 0 0
Part 2: Median DoR per investigator assessment of RECIST 1.1 criteria
Assessment method [11] 0 0
The DoR will be calculated as the time from the date of initial tumor response (CR or PR) to the date of first documented progressive disease (PD) or death from any cause, whichever occurs first.
Timepoint [11] 0 0
Every 8 weeks for the first 24 weeks, then every 12 weeks, up to 2 years
Secondary outcome [12] 0 0
Part 2: Median Progression free survival (PFS) per investigator assessment of RECIST 1.1 criteria
Assessment method [12] 0 0
PFS is defined as the time from the date of the first dose to the date of first PD per RECIST 1.1 criteria or death from any cause, whichever occurs first.
Timepoint [12] 0 0
Every 8 weeks for the first 24 weeks, then every 12 weeks, up to 2 years

Eligibility
Key inclusion criteria
* Part 1 only: Histologically confirmed adenocarcinoma of the prostate without evidence of neuroendocrine differentiation, signet cell, or small cell features.
* Part 2 only: Histologically confirmed SCC or the anus, melanoma, HNSCC, squamous NSCLC, or SCLC.
* Part 1 only: Received 1 prior ARAT for metastatic or non-metastatic, castration-sensitive or castration-resistant prostate cancer. A second ARAT regimen of <60 days used as bridging to lutetium-177 is permitted. Up to 3 total prior lines of therapy for mCRPC are permitted..
* Part 2 only: At least 1 prior line of systemic therapy for unresectable or metastatic disease and no more than 2 prior lines of cytotoxic chemotherapy. Participants with HNSCC or melanoma must have received prior PD-1 or PD-L1 inhibitor for advanced or metastatic disease.
* All participants must have = 1 metastatic lesion, according to RECIST 1.1 or PCWG3 criteria, that is present on magnetic resonance imaging (MRI), computed tomography (CT), or bone scan obtained = 28 days prior to initiation of study treatment.
* All participants must have tumor progression, according to disease-specific criteria, following their most recent anti-cancer therapy.
* All participants must have and available archival or formalin-fixed paraffin-embedded (FFPE) tumor tissue sample for participants with metastasis to internal organs
* All participants have acceptable physical condition and laboratory values.
* All participants of childbearing potential must agree to use highly effective methods of birth control.
* All participants must not be pregnant, planning to be pregnant, or breastfeeding.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.
* Part 1 only: Received >1 prior taxane-containing regimen for prostate cancer. A second taxane regimen of <60 days used as bridging for lutetium-177 is permitted.
* Part 1 only: Received >3 total prior therapies for mCRPC
* Part 1 only: Participants with known BRCA or ATM mutation (germline or somatic) are not eligible unless they received prior treatment with a PARP inhibitor where available, indicated and tolerated.
* Another hematologic or solid tumor = stage 1 malignancy that completed surgery, last dose of radiotherapy, or last dose of systemic anti-cancer therapy = 2 years from first dose of study treatment. Participants who had curative therapy for non-melanomatous skin cancer or for localized malignancy are eligible.
* Untreated, symptomatic central nervous system (CNS) metastasis.
* Prior treatment with any B7-H3 targeted agent for cancer,
* Contradictions to the use of corticosteroid treatment
* Prior stem cell, tissue, or solid organ transplant.
* Part 1 only: Use of products that have published anti-prostate cancer activity or are known to decrease PSA.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
13/06/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
23/01/2025
Sample size
Target
Accrual to date
Final
192
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Ramsay Health Care - Westmead Private Hospital - Westmead
Recruitment hospital [2] 0 0
The University of Queensland (UQ) - Princess Alexandra Hospital (PAH) - Woolloongabba
Recruitment hospital [3] 0 0
Cabrini Health- Malvern - Malvern
Recruitment hospital [4] 0 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment postcode(s) [2] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [3] 0 0
3144 - Malvern
Recruitment postcode(s) [4] 0 0
3000 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Louisiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Maryland
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
Minnesota
Country [7] 0 0
United States of America
State/province [7] 0 0
Ohio
Country [8] 0 0
United States of America
State/province [8] 0 0
Oregon
Country [9] 0 0
United States of America
State/province [9] 0 0
South Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Virginia
Country [11] 0 0
United States of America
State/province [11] 0 0
Washington
Country [12] 0 0
Belgium
State/province [12] 0 0
Brussles
Country [13] 0 0
Belgium
State/province [13] 0 0
Hainaut
Country [14] 0 0
Belgium
State/province [14] 0 0
Luxembourg
Country [15] 0 0
Belgium
State/province [15] 0 0
Namur
Country [16] 0 0
Belgium
State/province [16] 0 0
Gent
Country [17] 0 0
France
State/province [17] 0 0
AM
Country [18] 0 0
France
State/province [18] 0 0
Bas Rhin
Country [19] 0 0
France
State/province [19] 0 0
Gironde
Country [20] 0 0
France
State/province [20] 0 0
Herault
Country [21] 0 0
France
State/province [21] 0 0
Ile De France
Country [22] 0 0
France
State/province [22] 0 0
Ille Et Vilaine
Country [23] 0 0
France
State/province [23] 0 0
Sarthe
Country [24] 0 0
France
State/province [24] 0 0
Val De Marne
Country [25] 0 0
France
State/province [25] 0 0
Brest
Country [26] 0 0
France
State/province [26] 0 0
Paris
Country [27] 0 0
Italy
State/province [27] 0 0
TO
Country [28] 0 0
Italy
State/province [28] 0 0
Venice
Country [29] 0 0
Italy
State/province [29] 0 0
Florence
Country [30] 0 0
Italy
State/province [30] 0 0
Padova
Country [31] 0 0
Italy
State/province [31] 0 0
Trento
Country [32] 0 0
Korea, Republic of
State/province [32] 0 0
Daegu
Country [33] 0 0
Korea, Republic of
State/province [33] 0 0
Kyonggi
Country [34] 0 0
Korea, Republic of
State/province [34] 0 0
Gwangju
Country [35] 0 0
Korea, Republic of
State/province [35] 0 0
Seoul
Country [36] 0 0
Poland
State/province [36] 0 0
Mazowieckie
Country [37] 0 0
Poland
State/province [37] 0 0
Wlkp
Country [38] 0 0
Poland
State/province [38] 0 0
Zachodniopomorskie
Country [39] 0 0
Spain
State/province [39] 0 0
Barcelona
Country [40] 0 0
Spain
State/province [40] 0 0
Seville
Country [41] 0 0
Spain
State/province [41] 0 0
Lugo
Country [42] 0 0
Spain
State/province [42] 0 0
Madrid
Country [43] 0 0
United Kingdom
State/province [43] 0 0
Surrey
Country [44] 0 0
United Kingdom
State/province [44] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
MacroGenics
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Public notes

Contacts
Principal investigator
Name 0 0
Liudmila Schafer, M.D.
Address 0 0
MacroGenics
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT05551117